Valruzia

[Aethan]

Valruzia Announces first Influenza vaccine offering five-year protection

The announcement constitutes another landmark breakthrough by the Valruzian National Centre for Scientific Research (NCBN) and the nation, at the forefront of global biomedical innovation

August 5692

NCBN President Blanka Drewniak during the announcement of the new influenza supervaccine 

---

In a press conference this morning, the minister of Science and Research Maja Polcyn and the minister Health Julita Czech of Health confirmed what had already sparked widespread speculation in scientific circles: researchers at the Valruzian National Centre for Scientific Research (NCBN by its abbreviation) have successfully developed the world’s first Influenza vaccine capable of providing five years of protection, in a sharp contrast to current one-year existent vaccines.

This new vaccine, marketed as ValFlu-5, has completed Phase III clinical trials involving over 42,000 volunteers across Valruzia, with preliminary data –already submitted for peer review – showing a robust 92% reduction in influenza-related hospitalizations and broad protection against multiple circulating strains, including Influenza A (H1N1 and H3N2) and Influenza B.

NCBN President Blanka Drewniak congratulated the research team, calling the achievement “a historic day for Valruzian science and for global public health overall". According to NCBN’s scientific director, Dr. Irena Volanski, the vaccine combines several cutting-edge technologies that had never before been successfully integrated into a single immunization platform.
“For decades, scientists worldwide have tried to stabilize the hemagglutinin stem. We have finally managed to do so in a way that is scalable, reproducible and safe” Volanski said.

The hemagglutinin stem (HA-stem) is a highly conserved region of the influenza virus (which means it rarely mutates) unlike the head region, which changes constantly and it is basically what - until now – forces annual vaccine updates in the global population. One of the main problems that scientists encountered is that the HA-stem is normally unstable when removed from the full protein structure, but NCBN researchers report that they achieved full structural stabilization of this HA-stem using a novel combination of intermolecular bridge engineering and a nanoscale protein scaffold. Exact details remain confidential due to intellectual property considerations, as to avoid reproducibility outside of Valruzia for the moment. 

Once stabilized, the HA-stem is displayed on a self-assembling ferritin-based nanoparticle, presenting multiple stem copies in a highly organized pattern that triggers powerful, long-lasting antibody responses.

“The multivalent presentation is what it's really groundbreaking” Volanski explained. “Our immune system recognizes it as a structured, virus-like object, but it poses no risk of infection in ourselves”

Now, that's the first part of the vaccine, as explained in the widely-attended conference in the main hall of the NCBN headquarters. ValFlu-5 includes also a second, independent component: a next-generation mRNA construct that encodes two highly conserved internal proteins of Influenza, NP (nuleoprotein) and M1 (matrix protein 1). This component triggers a robust T-cell immune response, enabling the body to eliminate infected cells even when the virus mutates its surface proteins, as it is not targetting them but those below that surface.

The mRNA element is combined with a slow-release adjuvant known as VZ-731, developed also inside the walls of the NCBN, and whose precise formulation has not been disclosed as the Ministry of Health describes it as “strategic and powerful biomedical modern technology”

Now, the five-year duration of this novel vaccine is attributed to the combination of 1: the broad, cross-reactive antibodies targeting the stabilized HA-stem; 2: a durable T-cell memory against NP and M1; and 3: a long-term activation of antigen-presenting cells thanks to the slow-release adjuvant. It's the combination of these three points what makes this vaccine come on the top of all others. Clinical trial data show that after 48 months, participants maintain high neutralizing antibody levels well above protective thresholds, with predictive modelling estimating an average protection window of 4.7 to 5.6 years. It is expected however that the vaccine will not be made available to the public until at least 3 more years, when the window period testing for its efficiency is reached, and only then, if proved definitively successful, will be included in Valruzia's vaccine system and sent to hospitals. If regulatory approval proceeds without more delay, ValFlu-5 could be incorporated then into Valruzia's national immunization schedule in 3 years, replacing then the annual flu shot with a purposed five-year revaccionation cycle for adults and high-risk groups. A pediatric formulation might then follow next.

Of course, some experts within the NCBN also urge caution. Virologist Dr. Sabine Kumara notes that the Influenza virus "is always evolving", and that while this novel vaccine offers "unusually broad protection", no vaccine against Influenza can ever be entirely universal. Also, the leading research group of Dr. Volanski has already reached out to friendly nations around the globe such as Kalistan, Dundorf, Istalia and Xsampa to start trials with patients abroad, as to see whether it is equally efficient.

The Barela administration has of course praised the achievement, highlighting it as further evidence of Valruzia’s “global leadership in advanced biomedical research” especially following major investments in the national biotech sector by successive governments and the announcement of NOVA Pharma almost 40 years ago now of the first cure against rabies, now widespread throughout Terra.